



PRESS KIT CORPORATE

REGENERATE
& EVOLVE.

INDEX.

FIDIA PHARMACEUTICALS AT A GLANCE.	3
A PIONEER IN HYALURONIC ACID.	5
EVOLUTION AND GROWTH TRACK.	6
INNOVATION, RESEARCH AND DEVELOPMENT.	8
THERAPEUTIC AREAS COVERED.	10
CORPORATE CULTURE.	12
CARE FOR THE ENVIRONMENT AND PEOPLE.	13

FIDIA FARMACEUTICI AT A GLANCE.

Fidia Farmaceutici is an **Italian multinational company**, a world leader in the **research, development, production and marketing of solutions based on hyaluronic acid and its derivatives**, which have secured it a leading global role in **viscosupplementation**.

The company traces its origins back to **1946**, the year it was founded in **Bologna** before relocating its headquarters to **Abano Terme (PD)** in **1959**, and is now a **fully integrated pharmaceutical company**, capable of covering the entire life cycle of its products, from research and development to production, from logistics to marketing and sales.

The company has a production plant and research and development laboratories in Abano Terme (PD), a specialised research unit in Noto (SR) and its own offices in Lombardy and the Marche region.

Fidia's activities focus on the development of **innovative therapeutic solutions** with the aim of meeting the diverse needs of healthcare professionals and patients, whilst maintaining a focus on conditions with a significant social and economic impact, age-related diseases and other clinically relevant conditions.

With a strong commitment to internationalisation, Fidia distributes its products in over 120 countries thanks to a well-established network of partners and distributors and sales offices in key global markets, including **Austria, Bulgaria (branch), Egypt, France, Germany, Moldova, Poland, the United Kingdom, the Czech Republic, Romania, Russia, Slovakia, the United States, Spain, Switzerland, Turkey and the MENA region**.



Patents: more than 1,500, of which more than 1,250 relate to hyaluronic acid



Turnover: over €538 million, of which 54% generated abroad

COMPANY DATA 2025

People: over 1,700 worldwide



Global presence: more than 120 countries, 17 branches

Health&Wellness Care



Joint Care



Eye Care



Specialty Care



Skin Care



THERAPEUTIC AREAS

A PIONEER IN HYALURONIC ACID.

Fidia Farmaceutici is one of the absolute pioneers in hyaluronic acid (HA): **in 1963, it launched its first HA-based product**, paving the way for a path of innovation that has led it, over the years, to become the leading international authority on the research, technological development, production and marketing of this polymer.

Since then, the company has successfully harnessed the potential of HA – a polysaccharide naturally present in the human body, discovered in 1934 by scientists Karl Meyer and John Palmer – transforming it into a versatile technological platform that can be used across a wide range of therapeutic areas, thanks to the ability to develop, modify and functionalise it with different molecular weights.

Rooted in a culture focused on innovation, **Fidia is fully integrated into the production of hyaluronic acid, managing all stages of the production cycle in-house** – from extraction, fermentation and biotechnological processes right through to the development of the finished medicinal product – and ensuring high quality standards, full control over performance, traceability and safety throughout the entire supply chain



Today, with **over 60 years' experience and a portfolio of more than 1,250 patents dedicated to hyaluronic acid** (out of over 1,500 active ingredients globally), Fidia continues to lead the evolution of HA, developing solutions for use in joint conditions (osteoarthritis and tendinopathies), tissue repair (acute and chronic injuries), eye surgery, aesthetic medicine and as a carrier for pharmacologically active molecules.

EVOLUTION AND GROWTH TRACK.

Fidia is pursuing ambitious growth plans which include, amongst other activities, the opening of branches in strategic areas, international expansion into new territories and diversification into new business areas. Over the years, Fidia has strengthened its international presence, expanding its sales network to over 120 countries worldwide, thanks to its own branches in areas of high strategic value and a well-established network of partners and distributors operating in the pharmaceutical and biomedical sectors.

This growth has largely been driven by the acquisition of companies, products and technologies as part of a strategy aimed at expanding markets, the product portfolio and know-how.



● 2016

Acquisition of Biofarmitalia, a company based in Paderno Dugnano (MI), which has enabled the Group to expand its expertise in the development of new technologies for cosmetic and pharmaceutical applications, such as transdermal patches, impregnated matrices, patches and dynamic controlled-release devices, capable of delivering active ingredients via dermal, transdermal and oral routes.



● 2017

Acquisition of the Sooft Group, through which Fidia has strengthened its presence in ophthalmology, diversifying and refining its offering with a comprehensive range of products – eye drops, supplements and medical devices – under established brands.

● 2018

Acquisition of Soluciones Bioregenerativas SL, a Spanish company operating in the regenerative medicine sector, through which Fidia consolidates its expertise and strengthens its position in the field, expanding its range of products and therapies in the osteoarticular, dermatology and aesthetic medicine sectors.

● 2021

Completion of an acquisition from Sanofi relating to an integrated portfolio of anti-inflammatory drugs, which has enriched Fidia's product portfolio and strengthened its international presence.

● 2023

Entry into the Polish market through the acquisition of a number of eye care products and a vitamin D-based dietary supplement from the Polish subsidiary of Unipharm, a privately-owned US-based pharmaceutical company specialising in the development and marketing of over-the-counter (OTC) medicines and nutritional products.



● 2024

Acquisition of 100% of the ophthalmic business of Sanifarma, a leading Italian company in the field of eye care within the pharmacy sector, which also operates in the large-scale retail and online channels and in the sale of disposable contact lenses.

In the same year, Fidia further consolidated its presence in the pharmaceutical sector through two significant strategic transactions.



On the one hand, it has signed a commercial agreement with the multinational Novartis, a leader in the development of innovative medicines, for the distribution of six ophthalmic medicinal products intended for the treatment of glaucoma. On the other hand, it has completed the most significant acquisition in its recent history, through an agreement with Sanofi to integrate into its portfolio gynaecological medicines of high therapeutic value, classified as Medicines of Great Therapeutic Interest (MITM) and included in the World Health Organisation's (WHO) List of Essential Medicines.

● 2025

Inauguration in Abano Terme of a new department dedicated to biologics and a specialist Training Centre for doctors and surgeons, reinforcing Fidia's commitment to advanced training and the development of technologies to support clinical practice.

INNOVATION, RESEARCH AND DEVELOPMENT.

Fidia carries out extensive **Research & Development** activities in areas with high scientific and commercial potential, drawing on numerous collaborations with centres of excellence in both Italy and abroad.

At the two sites in **Abano Terme (PD)** and **Noto (SR)**, numerous projects are underway covering all stages of development: from discovery through preclinical trials to clinical programmes. The research programmes focus on therapeutic areas with high scientific potential and relevance for patients, confirming the company's role as a driver of innovation in its sector.



Abano Terme (PD)



Noto (SR)



The company has been investing in research into hyaluronic acid for over 60 years, during which time it has conducted more than 310 clinical trials, treating over 20 million patients with intra-articular hyaluronic acid since 1987.

The Group can draw on an extensive and robust portfolio of patents, reflecting a long scientific tradition, and a portfolio of clinical trials that attests to its international leadership in the field of hyaluronic acid.

As further recognition of the excellence of its research, Fidia has been granted Orphan Drug designations by both the FDA and the EMA.

RESEARCH IN THE PIPELINE.

Fidia's pipeline comprises medicinal products resulting from its own research and development in collaboration with international centres of excellence.

Oncofid®B	Bladder cancer	Phase III
Oncofid®M	Pleural mesothelioma	Preclinical phase
Injectable Collagenase	Dupuytren's contracture	Phase II
	Peyronie's disease	Phase I
	Moderate/severe cellulite	Preclinical phase
FID 136	OA/RA (Nrf2 activator)	Preclinical phase
FID 182	LHON	Preclinical phase
FID 333	Post-operative pain management	Preclinical phase
FID 337	Osteoarthritis	Preclinical phase

CONTRACT MANUFACTURING.

Thanks to its proven expertise and ongoing investment in industrial development and process efficiency, Fidia is now a **reliable partner for contract manufacturing (CMO)**.

The high technological standard of our facilities, combined with our ability to manage the entire production chain, offers client companies the opportunity to **optimise resources and processes**, whilst maintaining high standards of quality, safety and regulatory compliance.



THERAPEUTIC AREAS COVERED.


The company focuses on various therapeutic areas to provide effective solutions for patients and healthcare professionals.



EYE CARE

In this area, Fidia is committed to safeguarding eye health through research, innovation and patient-centred solutions, covering the full spectrum of major eye conditions. The acquisition of **Sooft** in 2017 expanded the company's long-standing expertise in the use of hyaluronic acid-based viscoelastic products for ophthalmic surgery, enriching its portfolio with medicines, medical devices, supplements and technologies dedicated to **corneal cross-linking**.

Today, the range includes treatments for conditions such as **dry eye, accommodative asthenopia, infections and inflammation of the ocular surface, corneal oedema, vitreous disorders, macular degeneration, diabetic retinopathy and glaucoma**.



HEALTH&WELLNESS CARE

Fidia is committed to improving people's health and wellbeing by offering accessible, effective and easy-to-use solutions for daily care and emotional balance.

Through Health & Wellness Care, the therapeutic division dedicated to the pharmacy channel, Fidia ensures that patients and consumers have direct, immediate and straightforward access to solutions that promote wellbeing and help improve their health.



JOINT CARE

In this area, Fidia offers integrated, patient-centred solutions for the treatment of osteoarticular disorders, with an approach ranging from dietary supplements to the most advanced therapies. The available options include **intra-articular** infiltrations of hyaluronic acid for the management of osteoarthritis and cartilage damage caused by trauma or functional overload, as well as **peritendinous** injections aimed at pain relief and improving elasticity in cases of tendinopathy.

The range also includes **oral chondroprotection** solutions to support joint physiology over time. To round off this therapeutic programme, Fidia has expanded its expertise into the field of **Regenerative Medicine**, developing a range dedicated to **Autologous Biological Therapy**. Thanks to a closed-loop system for the processing of **PRP, bone marrow concentrate (BMC) and micro-fractured adipose tissue enriched with SVF**, the company offers advanced and personalised clinical protocols, designed to promote functional recovery in major musculoskeletal conditions.



In the **Skin Care** sector, Fidia is committed to addressing the full spectrum of skin health needs, offering innovative and scientifically advanced solutions in the fields of **Wound Care, Derma Care and Aesthetic Care**. Building on its recognised leadership in hyaluronic acid and regenerative sciences, Fidia has, over the years, developed high-tech solutions for the management of acute and chronic wounds and has introduced the concept of **biostimulation** into aesthetic medicine, thanks to a portfolio of injectable treatments that enhance a person's natural identity through biocompatible, biodegradable and effective solutions.

This expertise is complemented by the company's entry into the cosmetics sector with a high-tech skincare range based on hyaluronic acid and its patented chemical modifications, thereby extending an integrated and scientifically grounded approach to skin care, protection and wellbeing.



With an approach focused on prevention and the management of unmet medical needs, Fidia operates in strategic fields such as **neuroscience, cardiovascular health, urogynaecology and infectious diseases**, offering safe and effective treatments, including nutraceuticals and exclusive hyaluronic acid derivatives.




CORPORATE CULTURE.

Fidia's values form the foundation of its identity and guide the way it operates and interacts with all its **stakeholders**, shaping a shared corporate culture that guides day-to-day decisions and working practices.

Inspired by the principles of **Vision, Openness, Leadership and Accountability (VOLA)**, these translate into concrete competencies that guide the day-to-day actions of all teams and support **responsible and sustainable growth** in the long term.

At the same time, values such as connection, simplicity, positive energy and valuing people define a collaborative approach to relationships. In this **virtuous circle**, as evidenced by the National Certification for Gender Equality, Fidia actively promotes an **inclusive environment that values diversity and equity**, supporting the professional and personal development of its staff through **projects, continuous training and opportunities for growth**, in the belief that the uniqueness of individuals is a key driver of value and innovation for the entire company.



CARE FOR THE ENVIRONMENT AND PEOPLE.


Fidia recognises the importance of the transition towards a sustainable growth model, based on the responsible use of resources and an awareness of the impact that every production activity has on the environment and people.

The Group is committed to constantly monitoring its environmental, health and safety performance through regular risk assessments and the implementation of maintenance, prevention and improvement programmes.

With a view to continuous improvement, the production plants are equipped with Management Systems compliant with the **ISO 14001** standard. Furthermore, Fidia voluntarily participates in the international **Responsible Care** programme, which aims to promote the sustainable development of the chemical industry, and undergoes an annual **EcoVadis** assessment to monitor and improve its sustainability performance across the entire value chain.



Similarly, the **focus on people** is a cornerstone of the corporate culture. Fidia promotes professional and personal growth through training programmes based, first and foremost, on people's self-development – with a focus on self-management – and by fostering an open, collaborative working environment founded on diversity, equity and inclusion.



To support this approach, a Steering Committee was established in 2023 to implement the company's policy and strategic plan for gender equality, as well as to manage and monitor issues relating to inclusion, gender equality and integration. It is supported by an **internal DE&I committee** – comprising volunteers from various departments – which promotes awareness-raising initiatives, training and ongoing dialogue. Among the concrete results of this process are the **National Certification for Gender Equality (UNI/PdR 125:2022)**, the maintenance of a gender pay gap below the national average, and the presentation, in 2025, of the **Manifesto for Inclusive Language**, which sets out ten guiding principles for respectful and representative communication.



Company images are available in the Media Gallery at <https://www.fidiapharma.com/media-gallery/>.

The gallery contains photos of the company and its activities, which may be freely downloaded (JPEG) and used in both low and high resolution. If published, Fidia Farmaceutici S.p.A. must be cited as the source, with a link to the website www.fidiapharma.com.

Further images, corporate videos or footage can be requested at

communication@fidiapharma.it

www.fidiapharma.it